PRISM II: an open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury

被引：0
|
作者：
Flora M. Hammond
David N. Alexander
Andrew J. Cutler
Stephen D’Amico
Rachelle S. Doody
William Sauve
Richard D. Zorowitz
Charles S. Davis
Paul Shin
Fred Ledon
Charles Yonan
Andrea E. Formella
Joao Siffert
机构：
[1] Indiana University School of Medicine,Physical Medicine and Rehabilitation
[2] Rehabilitation Hospital of Indiana,undefined
[3] University of California,undefined
[4] Florida Clinical Research Center,undefined
[5] LLC,undefined
[6] Cornerstone Medical Group,undefined
[7] Baylor College of Medicine,undefined
[8] TMS NeuroHealth Centers,undefined
[9] MedStar National Rehabilitation Network,undefined
[10] CSD Biostatistics,undefined
[11] Inc.,undefined
[12] Avanir Pharmaceuticals,undefined
[13] Inc.,undefined
来源：
BMC Neurology | / 16卷
关键词：
Dextromethorphan; Quinidine; Pseudobulbar affect; Dementia; Brain injuries; Stroke; Neuropsychiatric symptoms; Center for neurologic study-lability scale;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] PRISM II: an open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury
    Hammond, Flora M.
    Alexander, David N.
    Cutler, Andrew J.
    D'Amico, Stephen
    Doody, Rachelle S.
    Sauve, William
    Zorowitz, Richard D.
    Davis, Charles S.
    Shin, Paul
    Ledon, Fred
    Yonan, Charles
    Formella, Andrea E.
    Siffert, Joao
    BMC NEUROLOGY, 2016, 16
  • [2] Erratum to: PRISM II: an open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury
    Flora M. Hammond
    David N. Alexander
    Andrew J. Cutler
    Stephen D’Amico
    Rachelle S. Doody
    William Sauve
    Richard D. Zorowitz
    Charles S. Davis
    Paul Shin
    Fred Ledon
    Charles Yonan
    Andrea E. Formella
    Joao Siffert
    BMC Neurology, 16
  • [3] PRISM II: an open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury (vol 16, 89, 2016)
    Hammond, Flora M.
    Alexander, David N.
    Cutler, Andrew J.
    D'Amico, Stephen
    Doody, Rachelle S.
    Sauve, William
    Zorowitz, Richard D.
    Davis, Charles S.
    Shin, Paul
    Ledon, Fred
    Yonan, Charles
    Formella, Andrea E.
    Siffert, Joao
    BMC NEUROLOGY, 2016, 16
  • [4] An open-label study to assess safety, tolerability, and effectiveness of dextromethorphan/quinidine for pseudobulbar affect in dementia: PRISM II results
    Doody, Rachelle S.
    D'Amico, Stephen
    Cutler, Andrew J.
    Davis, Charles S.
    Shin, Paul
    Ledon, Fred
    Yonan, Charles
    Siffert, Joao
    CNS SPECTRUMS, 2016, 21 (06) : 450 - 459
  • [5] An Open-Label Study to Assess Safety, Tolerability, and Effectiveness of Dextromethorphan/Quinidine for Pseudobulbar Affect (PBA) in Dementia, Stroke and Traumatic Brain Injury: PRISM II Combined Cohort Results for Patients Aged ≥65 Years
    Hammond, Flora
    Alexander, David N.
    Cutler, Andrew J.
    D'Amico, Stephen
    Doody, Rachelle S.
    Sauve, William
    Zorowitz, Richard D.
    Davis, Charles S.
    Shin, Paul
    Ledon, Fred
    Yonan, Charles
    Formella, Andrea E.
    Siffert, Joao
    AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, 2016, 24 (03): : S146 - S147
  • [6] PRISM II: Effectiveness of Dextromethorphan 20 mg/Quinidine 10 mg (NUEDEXTA®) for Treatment of Pseudobulbar Affect Secondary to Dementia, Stroke, or Traumatic Brain Injury: Combined Results of a Multicenter Open-Label Study
    Siffert, Joao
    Hammond, Flora
    Alexander, David
    Cutler, Andrew
    D'Amico, Stephen
    Doody, Rachelle
    Sauve, William
    Zorowitz, Richard
    Davis, Charles
    Shin, Paul
    Ledon, Fred
    Yonan, Charles
    Formella, Andrea
    NEUROLOGY, 2016, 86
  • [7] PRISM II: Effectiveness of Dextromethorphan 20 mg/Quinidine 10 mg (NUEDEXTA) for Treatment of Pseudobulbar Affect Secondary to Dementia, Stroke, or Traumatic Brain Injury: Combined Results of a Multicenter Open-label Study
    Hammond, Flora
    Siffert, Joao
    Alexander, David
    Cutler, Andrew J.
    D'Amico, Stephen
    Doody, Rachelle
    Formella, Andrea
    Ledon, Fred
    Sauve, William
    Shin, Paul
    Yonan, Charles
    Zorowitz, Richard
    NEUROPSYCHOPHARMACOLOGY, 2015, 40 : S365 - S366
  • [8] SAFETY, TOLERABILITY, AND EFFECTIVENESS OF DEXTROMETHORPHAN/QUINIDINE FOR PSEUDOBULBAR AFFECT IN TRAUMATIC BRAIN INJURY: PRISM-II
    Hammond, Flora
    Sauve, William
    Shin, Paul
    Ledon, Fred
    Davis, Charles
    Yonan, Charles
    Siffert, Joao
    JOURNAL OF NEUROTRAUMA, 2015, 32 (12) : A19 - A19
  • [9] PRISM II: An Open-Label Study to Assess the Safety, Tolerability, and Effectiveness of Dextromethorphan 20 mg/Quinidine 10 mg for Treatment of Pseudobulbar Affect Secondary to Dementia, Stroke, or Traumatic Brain Injury: Results from the Alzheimer's Disease/Dementia Cohort
    Doody, Rachelle S.
    D'Amico, Stephen
    Cutler, Andrew J.
    Shin, Paul
    Ledon, Frederic
    Yonan, Charles
    Siffert, Joao
    AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, 2015, 23 (03): : S163 - S164
  • [10] Safety, Tolerability, and Effectiveness of Dextromethorphan/Quinidine for Pseudobulbar Affect Among Study Participants With Traumatic Brain Injury: Results From the PRISM-II Open Label Study
    Hammond, Flora M.
    Sauve, William
    Ledon, Fred
    Davis, Charles
    Formella, Andrea E.
    PM&R, 2018, 10 (10) : 993 - 1003
12345